

Special Issue

Prostate Cancer: From Molecular Basis to Clinical Therapy

Message from the Guest Editors

Prostate cancer is still a great challenge worldwide. This Special Issue of *Biomedicines* focuses on recent advances in the understanding of the molecular events underlying prostate cancer, imaging of prostate cancer, prostate biopsy decisions, and the clinical treatment of prostate cancer. Treatment resistance, neuroendocrinial progression, targeted therapy, and immunotherapy are also discussed. The goal of this Special Issue is to stimulate research and clinical interest in this exciting field. In particular, we hope this Special Issue will improve our understanding of this malignant disease, and encourage physicians, urologists, and medical oncologists to share clinical decisions and improve treatment outcomes in patients with prostate cancer.

Guest Editors

Prof. Dr. Benyi Li

Department of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA

Dr. Qi Ma

Translational Research Laboratory for Urology, The Affiliated Hospital, Ningbo University, Ningbo, China

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



mdpi.com/si/176896

Biomedicines

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

biomedicines@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/biomedicines)

[biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](http://mdpi.com/journal/biomedicines)

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

